This document summarizes research into discovering inhibitors for the histone-lysine N-methyltransferase SETD2 through in silico methods. The researchers generated pharmacophore models of the S-adenosyl methionine binding site of SETD2 and screened a database of over 150,000 compounds. Top hits with predicted binding energies below -9 kcal/mol were identified, and future work will involve refining models, screening more databases, and testing top compounds in assays. The goal is to identify novel SETD2 inhibitors for potential use in cancer treatment targeting epigenetic changes.